晚期糖基化终末产物抑制剂在心血管疾病中的研究进展
摘要
晚期糖基化终末产物(AGEs)通过各种机制参与心血管疾病的发生发展,AGEs抑制剂可通过减轻AGEs负荷而成为心血管病治疗的药物。本文分类概述了AGEs抑制剂的作用机制及临床应用,综合评价各类AGEs抑制剂的作用特点,便于其临床的合理应用。
出处
《心血管康复医学杂志》
CAS
2012年第3期332-334,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
基金
福建省自然科学基金(2010J1127)
参考文献17
-
1Ko SY,Lin YP,Lin YS. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species[J].Free Radical Biology and Medicine,2010,(03):474-480.
-
2Coker LH,Wagenknecht LE. Advanced glycation end products,diabetes,and the brain[J].Neurology,2011,(14):1326-1327.
-
3Chang JB,Chu NF,Syu JT. Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middleaged and elderly diabetic patients[J].LIPIDS IN HEALTH AND DISEASE,2011,(01):228.
-
4Yah SF,Ramasamy R,Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease[J].Expert Reviews In Molecular Medicine,2009.e9.
-
5林虹,朱鹏立.晚期糖基化终末产物及其受体在原发性高血压中的作用机制[J].国际老年医学杂志,2010,31(4):165-170. 被引量:8
-
6Kilhovd BK,Juutilainen A,Lehto S. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men:a population-based 18-year follow-up study[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2005,(04):815-820.
-
7Prévost G,Bulckaen H,Gaxatte C. Structural modifications in the arterial wall during physiological aging and as a results of diabetes mellitus in a mouse model:are the changes comparable[J].Diabetes & Metabolism,2011,(02):106-111.
-
8Peng X,Ma J,Chen F. Naturally occurring inhibitors against the formation of advanced glycation end-products[J].Food Funct,2011,(06):289-301.
-
9Little WC,Zile MR,Kitzman DW. The effect of alagebrium chloride (ALT-711),a novel glucose cross link breaker,in the treatment of elderly patients with diastolic heart failure[J].Journal of Cardiac Failure,2005,(03):191-195.doi:10.1016/j.cardfail.2004.09.010.
-
10Voziyan PA,Hudson BG. Pyridoxamine as a multifunctional pharmaceutical:targeting pathogenic glycation and oxidative damage[J].Cellular and Molecular Life Sciences,2005,(15):1671-1681.
二级参考文献43
-
1Singh R, Barden A, Mori T, et al. Advanced glycation end - products: a review [ J ]. Diabetologia, 2001, 44: 129-146.
-
2Schmidt AM, Vianna M, Gerlaeh M, et al. Isolation and eharacterisation of two binding proteins for advanced glycosylation endproduets from bovine lung which are present on the endothelial cell surface [J]. Biol Chem, 1992, 267: 14987-14997.
-
3Li J, Schmidl AM. Charaeterization and functional analysis of the prnmoter of RAGE: the receptor for advanced glycation end products [ J ]. Biol Chem, 1997, 272: 16498-16506.
-
4Diego G, Colomba F, Enzo E. Soluble receptor for advanced glyeation end products: from disease marker to potential therapeutic target [ J ]. Curr Med Chem, 2006, 13: 1971 - 1978.
-
5Sudesh V, Vicki G, Pawan S. Role of advanced glycation end products in hypertension and athcrosclero sis: therapeutic implication [ J ]. Cell Biochem Biophy, 2007, 49: 48-63.
-
6Morgan P, Dean R, Davies M. lnaetlvation of celluar enzymes by carbonyls and protein - bound glycation/ glycoxidation products [ J ]. Arch Brochem Biophy, 2002, 403:259 -269.
-
7Wang X, Desai K, Chang T, et al. Vascular methylglyoxal metabolism and the development of hypertension [J]. Hypertension, 2005, 16: 173-179.
-
8Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells [J]. Hypertension, 2002, 39: 809-814.
-
9Alp NJ, Channon KM. Regulation of endnthchal nitric oxide synthase by tetrahydrobiopetin in vascular disease [J]. Arterioscler Thromb Vasc Biol, 2004, 24:413- 420.
-
10Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilation in experimental diabetes [J]. Clin Invest, 1991, 87: 432- 438.
共引文献7
-
1袁音,朱鹏立,余惠珍,林帆.吡哆胺对血管紧张素Ⅱ诱导的人肾小管上皮细胞增殖的影响[J].福建医科大学学报,2012,46(2):90-94. 被引量:1
-
2周燕琼,金成,张英.晚期糖基化终末产物(AGEs)形成途径、检测方法和抑制手段研究进展[J].中国食品学报,2013,13(6):175-184. 被引量:26
-
3黄妙毅,刘志燕,刘安.慢性阻塞性肺疾病患者sRAGE与AGEs水平变化及意义[J].临床肺科杂志,2015,20(9):1678-1680. 被引量:4
-
4李业琼,叶山东,翟丽敏,胡闻.二甲双胍对2型糖尿病模型大鼠肾组织AGEs表达的影响[J].中国药理学通报,2016,32(5):703-707. 被引量:15
-
5李玲孺,王琦,王济,王前飞,杨玲玲,郑璐玉,张妍.Feasibility of Assessing Health State by Detecting Redox State of Human Body Based on Chinese Medicine Constitution[J].Chinese Journal of Integrative Medicine,2016,22(8):635-640. 被引量:1
-
6裴媛,王瑞,周贺伟.罗布麻治疗高血压作用机制的网络药理学研究[J].中南药学,2019,17(11):1997-2001. 被引量:9
-
7陈晶晶,马晓昌.基于网络药理学分析杞菊地黄丸治疗高血压的作用机制[J].中西医结合心脑血管病杂志,2022,20(13):2315-2321. 被引量:1
-
1郑立发,周建平,吕慧侠.我国药物新剂型研究进展[J].药学进展,2014,38(4):252-256. 被引量:5
-
2夏敬生.培哚普利的药理学特性及其在心血管病治疗中的应用[J].医药导报,1992,11(5):14-15.
-
3宋文宣.镁盐在心血管病治疗中的临床应用[J].中国医院药学杂志,1992,12(11):509-510.
-
4孙迪清,张兆芹,魏强,刘卫.心血管病治疗中的联合用药问题分析[J].中国药物应用与监测,2006,3(2):58-60. 被引量:3
-
5蒋长盛.钙拮抗剂在心血管病治疗中的新认识[J].国外医学(内科学分册),1998,25(4):150-153. 被引量:8
-
6高歌,唐扬章,高华康.钙拮抗剂药理学与心血管病治疗现状[J].中华综合临床医学杂志(北京),2004,6(11):106-109.
-
7谢伟蓉,曹阳,肖顺汉,刘明华.糖尿病血管病变的药物治疗进展[J].四川生理科学杂志,2008,30(1):35-37. 被引量:4
-
8郭松.他汀类药物在心血管病治疗中的应用[J].心血管病防治知识(学术版),2013,3(6):16-17. 被引量:3
-
9文川.中西药联用的配伍禁忌[J].中国社区医师,2005,21(20):18-18. 被引量:1
-
10唐慧娴,张振海,赵志英,吕慧侠.乳铁蛋白作为药物载体的研究进展[J].药学学报,2015,50(6):675-681. 被引量:11